Literature DB >> 3477018

Irritable bowel syndrome (IBS)--definition and pathophysiology.

N W Read.   

Abstract

The article presents some individual perceptions of the nature of the disease we call the Irritable Bowel Syndrome (IBS), and attempts to rationalise the variable presenting features, the influence of the psyche and the lack of pathological or biochemical markers. Among the topics discussed include the existence of recognisable subsets of the disease, the influence of mental stress, and the pathophysiology of the presenting symptoms. My impression is that IBS is a condition, in which the gut is hypersensitive and hyper-reactive to mechanical and chemical stimuli and as such, can be compared with asthma in the respiratory system. This hyper-reactivity could be caused by increased mucosal permeability, increased numbers and/or responses of effector cells such as mast cells or enterochromaffin cells, and enhancement of intrinsic nerve reflexes by increased activity of efferent vagal fibres.

Entities:  

Mesh:

Year:  1987        PMID: 3477018     DOI: 10.3109/00365528709090994

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

Review 1.  Current views on the aetiology and management of the irritable bowel syndrome.

Authors:  M J Hall; R E Barry
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

2.  Effect of coffee on distal colon function.

Authors:  S R Brown; P A Cann; N W Read
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

3.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

4.  How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form.

Authors:  K W Heaton; S Ghosh; F E Braddon
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.